Peptides for Labrador Retriever tendon and ligament injury
The short answer
Labrador Retrievers carry an elevated predisposition to tendon and ligament injury. The compounds investigated for it are BPC-157, TB-500, MGF. At a typical Labrador Retriever weight of 25–36 kg (55–79 lb), this breed falls in the large / giant breed dosing class. Critically, this breed carries a genetic trait that changes what is safe: Copper storage disease in certain Labrador lines
The Labrador Retriever-specific risk
⚠ Copper storage disease in certain Labrador lines
Some Labrador Retriever lines carry an inherited predisposition to hepatic copper accumulation. In these dogs, injectable GHK-Cu introduces a copper load the liver handles poorly. Baseline and follow-up liver values are essential, and the topical route — which produces minimal systemic absorption — is strongly preferred.
Tendon and ligament injury in Labrador Retrievers
Tendon and ligament tissue has a poor blood supply, which is the reason these injuries heal slowly and recur so readily. Repair tissue is also mechanically inferior to the original, so an inadequately rehabilitated injury tends to become a chronic one. This is where the largest share of the preclinical peptide literature sits — BPC-157's tendon-to-bone healing work and TB-500's cell migration research both target exactly this problem. It remains preclinical, but it is the most mechanistically coherent application on this site.
Dosing at Labrador Retriever body weight
Calculated for a 31 kg (68 lb) dog — the midpoint of the typical range for this breed.
| Compound | Dose at 31 kg | Frequency | Evidence |
|---|---|---|---|
| BPC-157 | 62–310 mcg | Once daily | Emerging evidence |
| TB-500 | 3.1–7.75 mg | Weekly TOTAL — split into 1-2 injections/week for a 2-4 week loading phase, then about half that weekly total for maintenance | Emerging evidence |
| MGF | 62–155 mcg | Daily or every other day | Preliminary / in vitro only |
Weigh your dog rather than using a breed average — an individual Labrador Retriever can sit well outside the typical range. Use the dose calculator for an exact figure.
Common questions
What peptides are used for tendon and ligament injury in Labrador Retrievers?+
BPC-157, TB-500, MGF are investigated for tendon and ligament injury. Note that Labrador Retrievers carry a specific genetic consideration: Copper storage disease in certain Labrador lines
How much should a Labrador Retriever be given?+
Labrador Retrievers typically weigh 25–36 kg (55–79 lb), placing them in the large / giant breed class. BPC-157: approximately 62–310 mcg at 31 kg. TB-500: approximately 3.1–7.75 mg at 31 kg. MGF: approximately 62–155 mcg at 31 kg. Weigh your dog rather than relying on a breed average.
Are Labrador Retrievers more prone to tendon and ligament injury?+
Yes. Labrador Retrievers carry an elevated predisposition to tendon and ligament injury. Strains, partial tears, and chronic tendinopathies in working, sporting, and active dogs.
References
- 1.CANINE STUDYHe L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588717
- 2.CANINE STUDYXu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
- 3.Vasireddi N, Nguyen HH, Ahmed WA, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025. PMID 40756949
- 4.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
- 5.Józwiak M, Bauer M, Kamysz W, Kleczkowska P Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals, 2025. PMID 40005999
- 6.Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. American Journal of Sports Medicine, 2026. PMID 41476424
- 7.Kleinman HK, Sosne G Thymosin β4 Promotes Dermal Healing. Vitamins and Hormones, 2016. PMID 27450738
- 8.Philp D, Kleinman HK Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Annals of the New York Academy of Sciences, 2010. PMID 20536453
- 9.Goldstein AL, Hannappel E, Sosne G, Kleinman HK Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 2012. PMID 22074294
- 10.Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma. Journal of Chromatography A, 2012. PMID 23084823
- 11.Delcourt V, Loup B, Bailly-Chouriberry L, et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and unapproved drugs. Drug Testing and Analysis, 2023. PMID 36482504
- 12.Goldspink G Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology, 2005. PMID 16024511
- 13.Kandalla PK, Goldspink G, Butler-Browne G, Mouly V Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mechanisms of Ageing and Development, 2011. PMID 21354439
Other conditions Labrador Retrievers are predisposed to: Hip dysplasia, Osteoarthritis, Cranial cruciate ligament (CCL) tear.
Where to source research peptides
Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.